Search

Becton Dickinson and Co

Fermé

SecteurSoins de santé

156.15 1.95

Résumé

Variation du prix de l'action

24h

Actuel

Min

156.08

Max

156.7

Chiffres clés

By Trading Economics

Revenu

-692M

-310M

Ventes

-538M

4.7B

P/E

Moyenne du Secteur

27.635

62.58

BPA

2.9

Rendement du dividende

2.64

Marge bénéficiaire

-6.576

Employés

60,000

EBITDA

-499M

709M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+14% upside

Dividendes

By Acuity

Rendement du dividende

Moyenne du Secteur

2.64%

2.19%

Prochains Résultats

6 août 2026

Date du Prochain Dividende

29 sept. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

945M

43B

Ouverture précédente

154.2

Clôture précédente

156.15

Sentiment de l'Actualité

By Acuity

50%

50%

152 / 340 Classement par Healthcare

Becton Dickinson and Co Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 juil. 2026, 19:26 UTC

Becton Dickinson and Co is trading higher, supported by gains in the Health Care Equipment sub-sector and maintaining a position above its 20-day moving average.

23 juil. 2026, 19:56 UTC

Becton Dickinson shares are lower, extending a five-session decline amid ongoing market concerns over corporate earnings and inflation pressures from rising oil prices.

21 juil. 2026, 19:36 UTC

Becton Dickinson is trading lower today, extending a trend of three consecutive daily declines. No specific news was identified to explain the movement.

20 juil. 2026, 20:14 UTC

Becton Dickinson remains roughly flat in after-market trading, positioned 1.12% above its 20-day moving average, but has declined for three consecutive sessions.

Comparaison

Variation de prix

Becton Dickinson and Co prévision

Objectif de Prix

By TipRanks

14% hausse

Prévisions sur 12 Mois

Moyen 178.25 USD  14%

Haut 204 USD

Bas 161 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

8 ratings

4

Achat

4

Maintien

0

Vente

Sentiment

By Acuity

152 / 340Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
help-icon Live chat